Drs. Friedlander, Koshkin on Long-Term Follow-Up of EV-103
By Terence Friedlander, MD, Vadim Koshkin, MD - Last Updated: June 15, 2023Terence Friedlander, MD, and Vadim Koshkin, MD, both of the University of California, San Francisco, highlight the 18-month outcomes data from the EV-103 study on enfortumab vedotin plus pembrolizumab as first-line treatment for metastatic urothelial carcinoma.
Related Posts
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.